Max Health Q4 Results: Profit, Revenue Surges But Margin Flat
Profit after tax surged 21% to Rs 376 crore in the January-March quarter, compared to Rs 311 crore in the corresponding period last year.
.png?rect=0%2C0%2C1093%2C615&auto=format%2Ccompress&fmt=avif)
Max Healthcare Institute Ltd. reported a solid growth in earnings during the fourth quarter of the financial year 2025.
Profit after tax surged 21% to Rs 376 crore in the January-March quarter, compared to Rs 311 crore in the corresponding period last year, according to financial results released on Tuesday.
For the whole year, profit grew 9% to Rs 1,392 crore, from Rs 1,278 crore in fiscal 2024.
Net revenue jumped 29% to Rs 2,326 crore versus Rs 1,799 crore in the year-ago period.
The hospital chain's operational profitability improved with earnings before interest, tax, depreciation and amortisation rising 26%, even as margin was flat.
Max Healthcare Institute Q4 Highlight
Revenue up 29% to Rs 2,326 crore versus Rs 1,799 crore
Ebitda up 26% to Rs 632 crore versus Rs 503 crore
Margin at 27.2% versus 27.3%
Net profit up 21% to Rs 376 crore versus Rs 311 crore
Bed occupancy for the quarter was at 75%, with Occupied Bed Days rising 30% year-on-year, a press statement said. The average revenue per occupied bed stood at Rs 77,100, as compared to Rs 76,800 in the corresponding quarter last fiscal.
The company reported a 28% growth in international patient revenue at Rs 202 crore, accounting for nearly 9% of the total income.
Besides, Max Health invested Rs 390 crore for ongoing expansion plans and upgradation of facilities at new units.
The board recommended a final dividend of Rs 1.5 per share for FY25, subject to shareholders' approval, which shall be paid within 30 days from the forthcoming Annual General Meeting.
Shares of Max Health fell 1.8% at Rs 1,165.3 apiece on the BSE, after the results, compared to over 1% decline in the benchmark Sensex. The stock has risen 40% in the last 12 months and 3% so far this year.
Fifteen out of 23 analysts tracking the company have a 'buy' rating on the stock, four recommend a 'hold' and four suggest a 'sell', according to Bloomberg data. The average of 12-month analysts' price target of Rs 1,108 implies a potential downside of 5%.
